RE:RE:RE:RE:RE:Pfizer Stockhouse is messing up the posting format and the below message should read:
For PADCEV and Pfizer's now owned Seagen acquired related ADC technology, Pfizer now owns, co-owns or has licensed rights to twelve patents in the United States and Europe that will expire between 2022 and 2031. Of these patents, Pfizer/Seagen owns or co-owns ten patents and have licensed rights to two patents.
https://www.sec.gov/Archives/edgar/data/1060736/000106073620000006/a10k2019.htm
Consequently, Pfizer's acquisition of ONCY's biologic pelareorep would provide Pfizer an additional 13 years of market exclusivity, pursuant to the IRA and from the time of approval, should Pfizer gain approval for the triplet combination of pelareorep with the doublet combination of Padcev + keytruda, which both face imminent patent expiration.
As a biologic pelareorep would be a candidate for IRA 13 year market exclusivity in this new single indication for pelareorep of Advanced/Metastatic Bladder Cancer, in combination with Pfizer/Seagen's Padcev + Merck's Keytruda.
Seagen was formely known as Seattle Genetics.
https://en.wikipedia.org/wiki/Seagen